Lilly ICOS' Cialis(R) (tadalafil) Reaches $1 Billion Global Sales Milestone
-- Latest figures confirm success of Cialis in the global ED marketplace --
BOTHELL, Wash. and INDIANAPOLIS, Ind., July 21 /PRNewswire/ -- Lilly ICOS
LLC (NYSE: LLY and Nasdaq: ICOS), marketer of tadalafil(1), a PDE5 inhibitor
indicated for the treatment of erectile dysfunction (ED), announced today that
the drug has achieved $1 billion in global sales since launching in Europe a
little more than two years ago(2).
In January 2005, tadalafil became the leading ED treatment in France, a
lead it has held through May, based on the latest market share data(3). It is
also performing very well in other countries, including the United Kingdom,
Italy, Germany, United States, Canada, Australia, Mexico and Brazil(4).
"We are very pleased with the performance of Cialis and the steady
development of the brand since its launch two years ago," said Rich Pilnik,
President of Lilly's EMEA region. "Millions of men suffer from ED and the
growth of the market demonstrates that patients are speaking to their
healthcare providers about ED and seeking treatment options."
Tadalafil was the second PDE5 inhibitor drug to become available in
Europe. It is currently marketed in approximately 100 countries including the
United States, Australia, Brazil, Mexico, Canada and across Europe and Asia.
"Passing the $1 billion mark is an important milestone for Lilly ICOS and
a great accomplishment for the Cialis team," said Paul Clark, Chairman and
Chief Executive Officer of ICOS Corporation. "Since 2003, men with erectile
dysfunction have had a choice of oral treatments for their condition -- a
condition which may impact on relationships and daily life."
About ED
ED is defined as the consistent inability to attain and maintain an
erection sufficient for sexual intercourse. ED affects an estimated 189
million men worldwide(5). Experts believe that 80 percent to 90 percent of ED
cases are related to a physical or medical condition, such as diabetes,
cardiovascular diseases, and prostate cancer treatment, while 10 percent to 20
percent are due to psychological causes(6). In many cases, however, both
psychological and physical factors contribute to the condition(7).
About Lilly ICOS LLC
Lilly ICOS LLC, a joint venture between ICOS Corporation and Eli Lilly and
Company, developed Cialis for the treatment of erectile dysfunction. ICOS
Corporation, a biotechnology company headquartered in Bothell, Washington, is
dedicated to bringing innovative therapeutics to patients. ICOS is working to
develop treatments for serious unmet medical conditions such as benign
prostatic hyperplasia, pulmonary arterial hypertension, cancer and
inflammatory diseases. Additional information about ICOS is available at
http://www.ICOS.com.
Lilly, a leading innovation-driven corporation is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Ind., Lilly provides answers -- through medicines and
information -- for some of the world's most urgent medical needs.
Except for historical information contained herein, this press release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking statements are
based on current expectations, estimates and projections about the industry,
management beliefs and certain assumptions made by the management of ICOS and
Lilly. Investors are cautioned that matters subject to forward-looking
statements involve risks and uncertainties, including economic, competitive,
governmental, technological, legal and other factors discussed in the two
companies' respective filings with the Securities and Exchange Commission,
which may affect the business and prospects of the two companies and Lilly
ICOS. Results and the timing and outcome of events may differ materially from
those expressed or implied by the forward-looking statements in this press
release. More specifically, there can be no assurance that Cialis will
achieve commercial success or that competing products will not pre-empt market
opportunities that might exist for the product.
(1) Cialis(R) is a registered trademark of Lilly ICOS LLC. All other
trademarks are the property of their respective owners.
(2) Data on File
(3) IMS Health, IMS MIDAS(TM), May 2005
(4) IMS Health, IMS MIDAS(TM), February 2005
(5) Data were extrapolated from Feldman HA, Goldstein I, Hatzichistou DG,
Krane RJ. Impotence and its Medical and Psychosocial Correlates: Results of
the Massachusetts Male Aging Study, Journal of Urology. Vol 151, 54-61,
January 1994 and World Population Projection Program of United Nations (2002
Revisions) with indirect standardization
(6) Diseases and Conditions: Impotence,
http://www.impotence.org/FAQ/index.asp Data accessed July 2005
(7) Lue, Tom F. Erectile Dysfunction. N Engl J Med 2000; 342, 24: 1802-
1813.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040122/LILLYICOSLOGO )
SOURCE Lilly ICOS LLC
